Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antiviral Prescribing Gaps Among Nonhospitalized High-Risk Adults

Matthew E. Levy, Evanette Burrows, Vanessa Chilunda, Pamala A. Pawloski, Phillip R. Heaton,Joseph Grzymski,Jason D. Goldman, Lisa M. McEwen,Dana Wyman,Andrew Dei Rossi,Hang Dai,Magnus Isaksson,Nicole L. Washington,Tracy Basler, Kevin Tsan,Jason Nguyen,Jimmy Ramirez,Efren Sandoval,William Lee,James Lu,Shishi Luo

CLINICAL INFECTIOUS DISEASES（2024）

引用 0|浏览5

暂无评分

摘要

Within a multistate clinical cohort, SARS-CoV-2 antiviral prescribing patterns were evaluated from April 2022-June 2023 among nonhospitalized patients with SARS-CoV-2 with risk factors for severe COVID-19. Among 3247 adults, only 31.9% were prescribed an antiviral agent (87.6% nirmatrelvir/ritonavir, 11.9% molnupiravir, 0.5% remdesivir), highlighting the need to identify and address treatment barriers.

查看译文

关键词

SARS-CoV-2,antiviral agents,nirmatrelvir,molnupiravir,electronic health records

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要